Clinical Trial Update: Therapeutic Effects of Maternal Melatonin Administration on Brain Injury and White Matter Disease [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating maternal melatonin to prevent brain injury and white matter disease in premature infants was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Injury
• Premature Birth
• White Matter Disease

Drugs mentioned

• Melatonin (melatonin)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Premature Birth | Phase 2, Phase 3 | Status: TERMINATED